...
机译:少女血症基因治疗后视网膜敏感性的变化
Univ Eye Hosp Ctr Ophthalmol Tubingen Germany;
Univ Eye Hosp Ctr Ophthalmol Tubingen Germany;
Univ Hosp Tubingen STZ Eyetrial Ctr Ophthalmol Tubingen Germany;
Univ Eye Hosp Ctr Ophthalmol Tubingen Germany;
Univ Eye Hosp Ctr Ophthalmol Tubingen Germany;
Univ Eye Hosp Ctr Ophthalmol Tubingen Germany;
Univ Eye Hosp Ctr Ophthalmol Tubingen Germany;
Univ Eye Hosp Ctr Ophthalmol Tubingen Germany;
Univ Hosp Tubingen STZ Eyetrial Ctr Ophthalmol Tubingen Germany;
Univ Hosp Tubingen STZ Eyetrial Ctr Ophthalmol Tubingen Germany;
Nightstar Therapeut London England;
Univ Eye Hosp Ctr Ophthalmol Tubingen Germany;
Ctr Ophthalmol Inst Ophthalm Res Tubingen Germany;
Univ Oxford Dept Clin Neurosci Nuffield Lab Ophthalmol Oxford England;
Univ Eye Hosp Ctr Ophthalmol Tubingen Germany;
Univ Hosp Tubingen STZ Eyetrial Ctr Ophthalmol Tubingen Germany;
AAV2-REP1; choroideremia; clinical trial; gene therapy;
机译:少女血症基因治疗后视网膜敏感性的变化
机译:多中心剂量升级阶段I / II临床试验中幼儿血症的视网膜基因治疗
机译:少女血症的巩膜坑对视网膜基因治疗的影响
机译:非病毒基因治疗和视网膜色素上皮组织工程治疗年龄相关性黄斑变性
机译:腺相关病毒8介导的脉络膜疾病基因治疗:体内和体外模型的临床前研究
机译:基因治疗的观点:脉络膜白血球症代表了一个具有挑战性的模型用于治疗其他遗传性视网膜变性。
机译:对血管血症接受视网膜基因治疗的患者视觉的有益影响